Resilience has become something of a buzzword in recent years – a cliché, even. The regular peaks and troughs that the biotech industry experiences lead many to prescribe ‘resilience’ as a cure-all for tough times. Being resilient is easier said than done when investors don’t seem interested, when politics are so unstable, when you hear […]
Novo Holdings participates in $372.5 million Series D financing of MapLight Therapeutics to advance differentiated CNS therapies Novo Holdings announced its participation in a $372.5 million Series D financing of MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders. The funds will support […]
Reports of a long-awaited ‘biotech spring’ have been sadly wide of the mark for a couple of years now. But as we roll into sultry August, could things actually be on the verge of blooming? Over the last few months, excited despatches have been landing thick and fast about the Chinese biotech boom, with the […]
Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi. Under the terms of the agreement, and subject to customary conditions, Vicebio shareholders will receive up to a total of US$1.6 billion, […]
Next Monday (July 28) is World Hepatitis Day, which recognises the huge global impact of this disease of the liver, which causes some 1.3 million deaths a year. Most of those result from infection with the Hepatitis B virus, which is commonly transmitted from mother to child during delivery, as well as through contact with […]
